Published in Cancer Law Weekly, June 18th, 2005
"Microtubules are among the most successful targets for anticancer therapies and for the development of new anticancer drugs," scientists in the United States explained. "A-432411 is a novel small molecule that destabilizes microtubules at high concentration and disrupts normal spindle formation at low concentration."
"A-432411 is an indolinone that is structurally different from other known synthetic microtubule inhibitors," noted Z.H. Chen and colleagues at Abbott Laboratories. "This compound is efficacious against a variety of human cancer cell lines, including...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.